Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

Mostrar otras versiones (1)

OBJECTIVES: The primary objective of MATIS is to determine the efficacy of ruxolitinib (RUX) or fostamatinib (FOS) compared to standard of care (SOC) with respect to reducing the proportion of hospitalised patients progressing from mild or moderate to severe COVID-19 pneumonia. Determine the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergis, Nikhil, Phillips, Rachel, Cornelius, Victoria, Katsarou, Alexia, Youngstein, Taryn, Cook, Lucy, Willicombe, Michelle, Pilay, Clio, Shturova, Tina, Almonte, Melanie, Charania, Asad, Turner, Richard, Kon, Onn Min, Cooke, Graham, Thursz, Mark, Cherlin, Svetlana, Wason, James, Milojkovic, Dragana, Innes, Andew J., Cooper, Nichola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039797/
https://www.ncbi.nlm.nih.gov/pubmed/33845867
http://dx.doi.org/10.1186/s13063-021-05190-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039797/
https://www.ncbi.nlm.nih.gov/pubmed/33845867
http://dx.doi.org/10.1186/s13063-021-05190-z

Ejemplares similares